drugset
drugset / Trial / NCT04981561

Safety and Tolerability of Zelquistinel in Normal Human Volunteers

NCT04981561 ↗

Phase 1 Completed 68 enrolled Syndeio Biosciences, Inc
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the safety and tolerability of single ascending doses of zelquistinel in normal human volunteers

Timeline

Start
2016-12-09
Primary completion
2017-12-21
Completion
2017-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Zelquistinel Small molecule 0.1 mg Oral
Subject Zelquistinel Small molecule 1 mg Oral
Subject Zelquistinel Small molecule 3 mg Oral
Subject Zelquistinel Small molecule 10 mg Oral
Subject Zelquistinel Small molecule 25 mg Oral
Subject Zelquistinel Small molecule 50 mg Oral
Subject Zelquistinel Small molecule 100 mg Oral

Indications

major depressive disorder